| ²é¿´: 5448 | »Ø¸´: 86 | |||
| ¡¾½±Àø¡¿ ±¾Ìû±»ÆÀ¼Û79´Î£¬×÷Õß°×¹â35Ôö¼Ó½ð±Ò 61.8 ¸ö | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
[×ÊÔ´]
ÃÀ¹úFDA¹ËÎÊÒ©Æ·Éú²úÆóÒµÑéÖ¤Åàѵ
|
|||
|
FUNDAMENTALS AND ESSENTIALS OF VALIDATION ÑéÖ¤»ù´¡¼°ÊµÖÊ Michael Anisfeld £¨Dr.Âó¿Ë.°²Ë¹·Æ¶ûµÃ£© Globepharm Consulting INTRODUCTION + REGULATORY ENVIRONMENT ½éÉÜ£«·¨¹æ»·¾³ VALIDATION BASICS ÑéÖ¤»ù´¡ÖªÊ¶ VALIDATION MASTER PLANS ÑéÖ¤Ö÷Îļþ PROCESS VALIDATION ¹¤ÒÕÑéÖ¤ UTILITIES VALIDATION ¹«ÓÃϵͳÑéÖ¤ CLEANING VALIDATION Çå½àÑéÖ¤ COMPUTER VALIDATION ¼ÆËã»úϵͳÑéÖ¤ ANALYTICAL METHOD VALIDATION ·ÖÎö·½·¨ÑéÖ¤ CASE STUDY °¸ÀýÑо¿ |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
ÑéÖ¤ |
» ²ÂÄãϲ»¶
ʹÓÃMolAICal·¢ÏÖµ°°×ÊÜÌåDZÔڵĻîÐÔ¿Ú´ü¼°Î»µã
ÒѾÓÐ0È˻ظ´
288·ÖÇóµ÷¼Á
ÒѾÓÐ0È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ150È˻ظ´
»ªÀíҩѧѧ˶Çóµ÷¼Á£¬×Ü·Ö324
ÒѾÓÐ0È˻ظ´
Ò»Ö¾Ô¸ËÕÖÝ´óѧ ÉúÎï¼¼ÊõÓ빤³Ì£¨086001£© ³õÊÔ323·Ö£¬Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
°ÄÃÅÀí¹¤´óѧÈ˹¤ÖÇÄÜÒ©Îï·¢ÏÖÖÐÐÄÕÐÊÕ2026¼¶²©Ê¿Ñо¿Éú£¨ÉêÇë-¿¼ºËÖÆ£©
ÒѾÓÐ10È˻ظ´
ÈýÄêʵÑéÊÒ¹¤×÷¾Àú£¬Ò»Ö¾Ô¸»ªÖÐũҵ´óѧ΢ÉúÎ×Ü·Ö288Çóµ÷¼Á
ÒѾÓÐ2È˻ظ´
ҩѧר˶É격
ÒѾÓÐ3È˻ظ´
070700Çóµ÷¼Á
ÒѾÓÐ1È˻ظ´
Çóµ÷¼Á×Ü·Ö327
ÒѾÓÐ0È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
ÔõÑù´ÓÃÀ¹úFDAÍøÕ¾ÉϲéÕÒ¼°ÏÂÔØÒ©Æ·ËµÃ÷Ê飿
ÒѾÓÐ11È˻ظ´
¡¾×ÊÔ´¡¿FDA-GMPÅàѵ×ÊÁÏ--ÔÁÏÒ©Éú²úÖеÄÈ·ÈÏÓëÑéÖ¤£¨ÖÐÓ¢¶ÔÕÕ£©
ÒѾÓÐ144È˻ظ´
¡¾×ªÌû¡¿º£ÆÕÈð¡°¶À¼ÒFDAÈÏÖ¤¡±µÄ½âÎö
ÒѾÓÐ9È˻ظ´
49Â¥2014-06-24 08:42:16
2Â¥2011-05-21 13:48:03
5Â¥2011-05-23 17:05:37
11Â¥2011-05-28 20:46:41
¼òµ¥»Ø¸´
yamaya4Â¥
2011-05-23 13:21
»Ø¸´
ÈýÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
ssyy98766Â¥
2011-05-27 16:22
»Ø¸´
ÎåÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
zhanglianglu7Â¥
2011-05-27 21:24
»Ø¸´
ÎåÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
jxjun1888Â¥
2011-05-28 10:12
»Ø¸´
ÎåÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
lucacai10Â¥
2011-05-28 19:45
»Ø¸´
ÎåÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
lzxfil12Â¥
2011-05-29 10:45
»Ø¸´
ÎåÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
ÎÞË«¹úÊ¿13Â¥
2011-05-30 15:33
»Ø¸´
ÎåÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
·½·½33814Â¥
2011-06-02 14:05
»Ø¸´
ÎåÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡














»Ø¸´´ËÂ¥